{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-009495","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2026-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.332887+00:00","generated_at":"2026-05-16T05:27:08.860094+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Merck Q4 Non-GAAP EPS $2.04 (+19% YoY); FY2026 guidance $5.00-$5.15 on Cidara charge","bullets":["Q4 2025 sales $16.4B (+5% GAAP EPS $1.19, Non-GAAP EPS $2.04).","Full-year sales $65.0B; Non-GAAP EPS $8.98 (+17% YoY).","KEYTRUDA $31.7B (+7%); WINREVAIR $1.4B; GARDASIL $5.2B (-39% on China weakness).","FY2026 sales guidance $65.5-$67.0B; Non-GAAP EPS $5.00-$5.15 includes ~$3.65 Cidara charge.","Acquired Verona Pharma and Cidara; 18 positive Phase 3 trials in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-009495","json":"https://secwatch.observer/filing/0001104659-26-009495.json","markdown":"https://secwatch.observer/filing/0001104659-26-009495.md","text":"https://secwatch.observer/filing/0001104659-26-009495.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/0001104659-26-009495-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/tm264564d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:27:08.860094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}